["{\n\"step_by_step_thinking\": \"Based on the provided documents, we can identify that rifabutin has a lower early bactericidal activity (EBA) compared to rifampicin. This is mentioned in 'The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis.' Additionally, it was found that peak plasma concentrations of rifabutin after the initial doses were approximately 7 times lower than those after the same dose size of rifampicin. This suggests that rifabutin may not be as effective as rifampicin for treating pulmonary TB.\n\nThe documents do not provide information on the half-life or drug-interactions of rifabutin compared to rifampicin, so options A and B cannot be conclusively determined.\n\nFinally, option C is false because rifabutin is mentioned as a potential replacement for rifampicin in combination treatment of patients with highly RAMP-resistant MAC bacteria, indicating that it may not be more efficacious against MAC.\n\nTherefore, the correct answer is D: Rifabutin is more efficacious for pulmonary TB as compared to rifampicin.\",\n\"answer_choice\": \"D\""]